Acadia Lands Japan Distribution Deal for DAYBUE With $30M Upfront
ACAD sits 19% above its 52-week low of $15.855.
Summary
Acadia signed Kyorin Pharmaceutical as its Japanese distributor for DAYBUE Stix (trofinetide) in Rett syndrome. Kyorin pays $30 million upfront, plus up to $45 million in milestones tied to an NHI price listing and net sales targets, with additional undisclosed payments. The deal monetizes a market Acadia has not yet commercialized directly and adds non-dilutive cash to a balance sheet that already held $976.4 million at the end of Q3. It follows the August European Commission approval of DAYBUE, extending the franchise's ex-U.S. reach. The upfront is modest next to Acadia's roughly $3.2 billion market value, so the milestone structure and any Japanese launch timing matter more than the headline cash.
At the time of this announcement, ACAD was trading at $18.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $15.86 to $30.96. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.